Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 ...
Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of ...
Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses.
Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between 5 and 12 months after ...
According to a 2021 review, nail psoriasis can be challenging to treat, but treatment is possible. The best approach for you may depend on your specific symptoms and their severity. Keep reading ...
Hepatitis B virus (HBV) infection is a significant global health issue, affecting over 200 million people worldwide. Chronic HBV infection can lead to severe liver diseases such as cirrhosis and ...